The adverse tumour characteristics, i.e. estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2)-positive disease, and advanced stage, could be related to a suppression of certain tumours during pregnancy and lactation due to pregnancy-related physiological changes and immunomodulation.19 This evidence concerns the gene ERBB2 and neoplasm.